TRIUMPH — 16 things I got wrong before I got it right
Posting this as a discussion rather than a claim: TRIUMPH — 16 things I got wrong before I got it right. What the glucagon arm is doing, as best anyone can say from public data. GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is…
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
[removed by moderator]
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
the energy-expenditure story is mechanistically interesting and clinically unproven
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
nothing here is available as a prescription product, so read every thread with that in mind
research-use-only material is not approved for human use, full stop
research-use-only material is not approved for human use, full stop
Agreed, and the glucagon arm is exactly why the comparison threads do not work.